Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants
The purpose of this study was to evaluate the effect of early administration of dexamethasone on the incidence of chronic lung disease (CLD) in high risk preterm infants and to evaluate the side effects of the early steroid administration. Randomised clinical trial. Neonatal intensive care unit. 50...
Gespeichert in:
| Veröffentlicht in: | Intensive care medicine 1999-07, Vol.25 (7), p.717-721 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 721 |
|---|---|
| container_issue | 7 |
| container_start_page | 717 |
| container_title | Intensive care medicine |
| container_volume | 25 |
| creator | ROMAGNOLI, C ZECCA, E VENTO, G DE CAROLIS, M. P PAPACCI, P TORTOROLO, G |
| description | The purpose of this study was to evaluate the effect of early administration of dexamethasone on the incidence of chronic lung disease (CLD) in high risk preterm infants and to evaluate the side effects of the early steroid administration.
Randomised clinical trial.
Neonatal intensive care unit.
50 infants at high risk of CLD were randomly assigned after 72 h of life to the dexamethasone group (n = 25) or to the control group (n = 25). The treated infants received dexamethasone intravenously from the 4th day of life for 7 days (0.5 mg/kg per day for the first 3 days, 0.25 mg/kg per day for the next 3 days and 0.125 mg/kg per day on the 7th day). The control group received no steroid treatment.
The incidence of CLD at 28 days of life and at 36 weeks' postconceptional age was significantly lower in the dexamethasone group than in the control group (p < 0.001). Moreover, infants in the dexamethasone group remained intubated and required oxygen therapy for a shorter period than those in the control group (p < 0.001). Hyperglycaemia, hypertension, growth failure and mainly hypertrophy of the left ventricle were the transient side effects associated with early steroid administration.
Early dexamethasone administration may be useful in preventing CLD, but its use should prudently be restricted to preterm infants at high risk of CLD. |
| doi_str_mv | 10.1007/s001340050935 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1017964669</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2629195331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-86534697ec1c763f5daaf6d0d2def3f70af8365d57641a82176c18d65f48a77b3</originalsourceid><addsrcrecordid>eNpd0MtrFTEUBvAgFnutLt1KEBdupuadzFJKfUChm7oeTvPopM4k1yQj7X9vyr3gY3Xg8OPjnA-hN5ScU0L0x0oI5YIQSUYun6EdFZwNlHHzHO0IF2wQSrBT9LLW-y61kvQFOqVEaCK12iF_CWV5xPtcW4IGC3b-AVbfZqg5eRxywW32eF_8L59azAnngO1ccooWL1u6wy5WD9XjmPAc7-ahxPrjyTdf1r4MkFp9hU4CLNW_Ps4z9P3z5c3F1-Hq-su3i09XgxVUt8EoyYUatbfUasWDdABBOeKY84EHTSAYrqTrlwsKhvV3LDVOySAMaH3Lz9CHQ-6-5J-br21aY7V-WSD5vNWJ9gZGJZQaO333H73PW0n9umkcmdFMMtXRcEC25FqLD9O-xBXKY0-anuqf_qm_-7fH0O129e4vfei7g_dHANXCEgokG-sfZzQfjeC_AfOmjGE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>992872526</pqid></control><display><type>article</type><title>Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>ROMAGNOLI, C ; ZECCA, E ; VENTO, G ; DE CAROLIS, M. P ; PAPACCI, P ; TORTOROLO, G</creator><creatorcontrib>ROMAGNOLI, C ; ZECCA, E ; VENTO, G ; DE CAROLIS, M. P ; PAPACCI, P ; TORTOROLO, G</creatorcontrib><description>The purpose of this study was to evaluate the effect of early administration of dexamethasone on the incidence of chronic lung disease (CLD) in high risk preterm infants and to evaluate the side effects of the early steroid administration.
Randomised clinical trial.
Neonatal intensive care unit.
50 infants at high risk of CLD were randomly assigned after 72 h of life to the dexamethasone group (n = 25) or to the control group (n = 25). The treated infants received dexamethasone intravenously from the 4th day of life for 7 days (0.5 mg/kg per day for the first 3 days, 0.25 mg/kg per day for the next 3 days and 0.125 mg/kg per day on the 7th day). The control group received no steroid treatment.
The incidence of CLD at 28 days of life and at 36 weeks' postconceptional age was significantly lower in the dexamethasone group than in the control group (p < 0.001). Moreover, infants in the dexamethasone group remained intubated and required oxygen therapy for a shorter period than those in the control group (p < 0.001). Hyperglycaemia, hypertension, growth failure and mainly hypertrophy of the left ventricle were the transient side effects associated with early steroid administration.
Early dexamethasone administration may be useful in preventing CLD, but its use should prudently be restricted to preterm infants at high risk of CLD.</description><identifier>ISSN: 0342-4642</identifier><identifier>EISSN: 1432-1238</identifier><identifier>DOI: 10.1007/s001340050935</identifier><identifier>PMID: 10470576</identifier><identifier>CODEN: ICMED9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Anti-Inflammatory Agents - administration & dosage ; Anti-Inflammatory Agents - adverse effects ; Anti-Inflammatory Agents - therapeutic use ; Biological and medical sciences ; Birth weight ; Bones, joints and connective tissue. Antiinflammatory agents ; Caffeine ; Chronic Disease ; Clinical trials ; Dexamethasone - administration & dosage ; Dexamethasone - adverse effects ; Dexamethasone - therapeutic use ; Disease prevention ; Drug Administration Schedule ; Extubation ; Female ; Gestational age ; Hospitals ; Humans ; hypertension ; Infant, Newborn ; Infant, Premature, Diseases - prevention & control ; Infants ; Injections, Intravenous ; Intensive care ; Lung ; Lung diseases ; Lung Diseases - prevention & control ; Male ; Medical sciences ; Neonates ; Newborn babies ; Oxygen therapy ; Pharmacology. Drug treatments ; Premature babies ; prevention ; Respiratory distress syndrome ; Respiratory Distress Syndrome, Newborn - complications ; Respiratory Distress Syndrome, Newborn - drug therapy ; Sepsis ; Side effects ; Steroids ; Treatment Outcome ; Ventilators</subject><ispartof>Intensive care medicine, 1999-07, Vol.25 (7), p.717-721</ispartof><rights>1999 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-86534697ec1c763f5daaf6d0d2def3f70af8365d57641a82176c18d65f48a77b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1873984$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10470576$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>ROMAGNOLI, C</creatorcontrib><creatorcontrib>ZECCA, E</creatorcontrib><creatorcontrib>VENTO, G</creatorcontrib><creatorcontrib>DE CAROLIS, M. P</creatorcontrib><creatorcontrib>PAPACCI, P</creatorcontrib><creatorcontrib>TORTOROLO, G</creatorcontrib><title>Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants</title><title>Intensive care medicine</title><addtitle>Intensive Care Med</addtitle><description>The purpose of this study was to evaluate the effect of early administration of dexamethasone on the incidence of chronic lung disease (CLD) in high risk preterm infants and to evaluate the side effects of the early steroid administration.
Randomised clinical trial.
Neonatal intensive care unit.
50 infants at high risk of CLD were randomly assigned after 72 h of life to the dexamethasone group (n = 25) or to the control group (n = 25). The treated infants received dexamethasone intravenously from the 4th day of life for 7 days (0.5 mg/kg per day for the first 3 days, 0.25 mg/kg per day for the next 3 days and 0.125 mg/kg per day on the 7th day). The control group received no steroid treatment.
The incidence of CLD at 28 days of life and at 36 weeks' postconceptional age was significantly lower in the dexamethasone group than in the control group (p < 0.001). Moreover, infants in the dexamethasone group remained intubated and required oxygen therapy for a shorter period than those in the control group (p < 0.001). Hyperglycaemia, hypertension, growth failure and mainly hypertrophy of the left ventricle were the transient side effects associated with early steroid administration.
Early dexamethasone administration may be useful in preventing CLD, but its use should prudently be restricted to preterm infants at high risk of CLD.</description><subject>Anti-Inflammatory Agents - administration & dosage</subject><subject>Anti-Inflammatory Agents - adverse effects</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Birth weight</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Caffeine</subject><subject>Chronic Disease</subject><subject>Clinical trials</subject><subject>Dexamethasone - administration & dosage</subject><subject>Dexamethasone - adverse effects</subject><subject>Dexamethasone - therapeutic use</subject><subject>Disease prevention</subject><subject>Drug Administration Schedule</subject><subject>Extubation</subject><subject>Female</subject><subject>Gestational age</subject><subject>Hospitals</subject><subject>Humans</subject><subject>hypertension</subject><subject>Infant, Newborn</subject><subject>Infant, Premature, Diseases - prevention & control</subject><subject>Infants</subject><subject>Injections, Intravenous</subject><subject>Intensive care</subject><subject>Lung</subject><subject>Lung diseases</subject><subject>Lung Diseases - prevention & control</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neonates</subject><subject>Newborn babies</subject><subject>Oxygen therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Premature babies</subject><subject>prevention</subject><subject>Respiratory distress syndrome</subject><subject>Respiratory Distress Syndrome, Newborn - complications</subject><subject>Respiratory Distress Syndrome, Newborn - drug therapy</subject><subject>Sepsis</subject><subject>Side effects</subject><subject>Steroids</subject><subject>Treatment Outcome</subject><subject>Ventilators</subject><issn>0342-4642</issn><issn>1432-1238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0MtrFTEUBvAgFnutLt1KEBdupuadzFJKfUChm7oeTvPopM4k1yQj7X9vyr3gY3Xg8OPjnA-hN5ScU0L0x0oI5YIQSUYun6EdFZwNlHHzHO0IF2wQSrBT9LLW-y61kvQFOqVEaCK12iF_CWV5xPtcW4IGC3b-AVbfZqg5eRxywW32eF_8L59azAnngO1ccooWL1u6wy5WD9XjmPAc7-ahxPrjyTdf1r4MkFp9hU4CLNW_Ps4z9P3z5c3F1-Hq-su3i09XgxVUt8EoyYUatbfUasWDdABBOeKY84EHTSAYrqTrlwsKhvV3LDVOySAMaH3Lz9CHQ-6-5J-br21aY7V-WSD5vNWJ9gZGJZQaO333H73PW0n9umkcmdFMMtXRcEC25FqLD9O-xBXKY0-anuqf_qm_-7fH0O129e4vfei7g_dHANXCEgokG-sfZzQfjeC_AfOmjGE</recordid><startdate>19990701</startdate><enddate>19990701</enddate><creator>ROMAGNOLI, C</creator><creator>ZECCA, E</creator><creator>VENTO, G</creator><creator>DE CAROLIS, M. P</creator><creator>PAPACCI, P</creator><creator>TORTOROLO, G</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7U1</scope><scope>7U2</scope><scope>C1K</scope></search><sort><creationdate>19990701</creationdate><title>Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants</title><author>ROMAGNOLI, C ; ZECCA, E ; VENTO, G ; DE CAROLIS, M. P ; PAPACCI, P ; TORTOROLO, G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-86534697ec1c763f5daaf6d0d2def3f70af8365d57641a82176c18d65f48a77b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>Anti-Inflammatory Agents - administration & dosage</topic><topic>Anti-Inflammatory Agents - adverse effects</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Birth weight</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Caffeine</topic><topic>Chronic Disease</topic><topic>Clinical trials</topic><topic>Dexamethasone - administration & dosage</topic><topic>Dexamethasone - adverse effects</topic><topic>Dexamethasone - therapeutic use</topic><topic>Disease prevention</topic><topic>Drug Administration Schedule</topic><topic>Extubation</topic><topic>Female</topic><topic>Gestational age</topic><topic>Hospitals</topic><topic>Humans</topic><topic>hypertension</topic><topic>Infant, Newborn</topic><topic>Infant, Premature, Diseases - prevention & control</topic><topic>Infants</topic><topic>Injections, Intravenous</topic><topic>Intensive care</topic><topic>Lung</topic><topic>Lung diseases</topic><topic>Lung Diseases - prevention & control</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neonates</topic><topic>Newborn babies</topic><topic>Oxygen therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Premature babies</topic><topic>prevention</topic><topic>Respiratory distress syndrome</topic><topic>Respiratory Distress Syndrome, Newborn - complications</topic><topic>Respiratory Distress Syndrome, Newborn - drug therapy</topic><topic>Sepsis</topic><topic>Side effects</topic><topic>Steroids</topic><topic>Treatment Outcome</topic><topic>Ventilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>ROMAGNOLI, C</creatorcontrib><creatorcontrib>ZECCA, E</creatorcontrib><creatorcontrib>VENTO, G</creatorcontrib><creatorcontrib>DE CAROLIS, M. P</creatorcontrib><creatorcontrib>PAPACCI, P</creatorcontrib><creatorcontrib>TORTOROLO, G</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>ROMAGNOLI, C</au><au>ZECCA, E</au><au>VENTO, G</au><au>DE CAROLIS, M. P</au><au>PAPACCI, P</au><au>TORTOROLO, G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants</atitle><jtitle>Intensive care medicine</jtitle><addtitle>Intensive Care Med</addtitle><date>1999-07-01</date><risdate>1999</risdate><volume>25</volume><issue>7</issue><spage>717</spage><epage>721</epage><pages>717-721</pages><issn>0342-4642</issn><eissn>1432-1238</eissn><coden>ICMED9</coden><abstract>The purpose of this study was to evaluate the effect of early administration of dexamethasone on the incidence of chronic lung disease (CLD) in high risk preterm infants and to evaluate the side effects of the early steroid administration.
Randomised clinical trial.
Neonatal intensive care unit.
50 infants at high risk of CLD were randomly assigned after 72 h of life to the dexamethasone group (n = 25) or to the control group (n = 25). The treated infants received dexamethasone intravenously from the 4th day of life for 7 days (0.5 mg/kg per day for the first 3 days, 0.25 mg/kg per day for the next 3 days and 0.125 mg/kg per day on the 7th day). The control group received no steroid treatment.
The incidence of CLD at 28 days of life and at 36 weeks' postconceptional age was significantly lower in the dexamethasone group than in the control group (p < 0.001). Moreover, infants in the dexamethasone group remained intubated and required oxygen therapy for a shorter period than those in the control group (p < 0.001). Hyperglycaemia, hypertension, growth failure and mainly hypertrophy of the left ventricle were the transient side effects associated with early steroid administration.
Early dexamethasone administration may be useful in preventing CLD, but its use should prudently be restricted to preterm infants at high risk of CLD.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>10470576</pmid><doi>10.1007/s001340050935</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0342-4642 |
| ispartof | Intensive care medicine, 1999-07, Vol.25 (7), p.717-721 |
| issn | 0342-4642 1432-1238 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1017964669 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Anti-Inflammatory Agents - administration & dosage Anti-Inflammatory Agents - adverse effects Anti-Inflammatory Agents - therapeutic use Biological and medical sciences Birth weight Bones, joints and connective tissue. Antiinflammatory agents Caffeine Chronic Disease Clinical trials Dexamethasone - administration & dosage Dexamethasone - adverse effects Dexamethasone - therapeutic use Disease prevention Drug Administration Schedule Extubation Female Gestational age Hospitals Humans hypertension Infant, Newborn Infant, Premature, Diseases - prevention & control Infants Injections, Intravenous Intensive care Lung Lung diseases Lung Diseases - prevention & control Male Medical sciences Neonates Newborn babies Oxygen therapy Pharmacology. Drug treatments Premature babies prevention Respiratory distress syndrome Respiratory Distress Syndrome, Newborn - complications Respiratory Distress Syndrome, Newborn - drug therapy Sepsis Side effects Steroids Treatment Outcome Ventilators |
| title | Early postnatal dexamethasone for the prevention of chronic lung disease in high-risk preterm infants |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-18T19%3A47%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20postnatal%20dexamethasone%20for%20the%20prevention%20of%20chronic%20lung%20disease%20in%20high-risk%20preterm%20infants&rft.jtitle=Intensive%20care%20medicine&rft.au=ROMAGNOLI,%20C&rft.date=1999-07-01&rft.volume=25&rft.issue=7&rft.spage=717&rft.epage=721&rft.pages=717-721&rft.issn=0342-4642&rft.eissn=1432-1238&rft.coden=ICMED9&rft_id=info:doi/10.1007/s001340050935&rft_dat=%3Cproquest_cross%3E2629195331%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=992872526&rft_id=info:pmid/10470576&rfr_iscdi=true |